Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Cleo Diagnostics Ltd

Healthcare AU COV

0.53AUD
0.03(4.95%)

Last update at 2026-03-10T02:51:00Z

Day Range

0.520.53
LowHigh

52 Week Range

0.310.90
LowHigh

Fundamentals

  • Previous Close 0.51
  • Market Cap75.27M
  • Volume10949
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.81043M
  • Revenue TTM2.56M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM 2.56M
  • Diluted EPS TTM-0.03

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -3.99913M -3.75923M -1.72950M -0.04393M
Minority interest - - - -
Net income -3.99913M -3.75923M -1.72950M -0.04393M
Selling general administrative 2.14M 1.58M 1.39M -
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation - 0.06M 0.04M -
Ebit - - - -
Ebitda - - - -
Depreciation and amortization - - - -
Non operating income net other - - - -
Operating income -3.89866M -3.61292M -1.57577M -0.02331M
Other operating expenses - - - -
Interest expense - 0.03M 0.11M -
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.00000M 0.03M 0.11M 0.00083M
Net interest income - 0.34M -0.11078M -
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense - - - -
Total revenue 1.18M 0.60M 0.11M 0.00000M
Total operating expenses 5.08M - - -
Cost of revenue - - - -
Total other income expense net - 0.24M 0.11M -
Discontinued operations - - - -
Net income from continuing ops - -3.75923M -1.72950M -
Net income applicable to common shares -3.99913M -3.75923M -1.72950M -0.04393M
Preferred stock and other adjustments - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 6.94M 9.88M 1.08M 0.24M
Intangible assets 0.36M 0.41M 0.46M 0.20M
Earning assets - - - -
Other current assets - - - -
Total liab 1.10M 0.49M 2.02M 0.29M
Total stockholder equity 5.83M 9.39M -0.94342M -0.04228M
Deferred long term liab - - - -
Other current liab - - - -
Common stock 13.71M - - 0.00000M
Capital stock - 13.71M 0.05M -
Retained earnings -7.87214M -5.53266M -1.77343M -0.04228M
Other liab - - - -
Good will - - - -
Other assets - - - -
Cash 0.75M 9.37M 0.24M 0.04M
Cash and equivalents 5.71M - - -
Total current liabilities 1.10M 0.49M 2.02M 0.29M
Current deferred revenue - - - -
Net debt - - 1.36M -
Short term debt 0.00000M - - 0.24M
Short long term debt - - 1.60M -
Short long term debt total - - - -
Other stockholder equity - - - -
Property plant equipment 0.03M - - -
Total current assets 6.55M 9.44M 0.58M 0.04M
Long term investments - - - -
Net tangible assets - - - -
Short term investments - - - -
Net receivables 0.07M 0.06M 0.03M 0.00086M
Long term debt - - - -
Inventory - - - -
Accounts payable - 0.44M 0.42M -
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income - - - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other - - - -
Deferred long term asset charges - - - -
Non current assets total - 0.44M 0.50M -
Capital lease obligations - - - -
Long term debt total 0.00000M - - 0.00000M
Breakdown 2025-06-30 2024-06-30 2023-06-30
Type yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30
Investments - -0.00305M -0.34024M
Change to liabilities - - -
Total cashflows from investing activities -0.01112M -0.00305M -0.34024M
Net borrowings - - -
Total cash from financing activities 0.00000M 11.17M 1.22M
Change to operating activities - - -
Net income - -3.75923M -1.72950M
Change in cash -2.91225M 9.13M 0.20M
Begin period cash flow - 0.24M 0.04M
End period cash flow - 9.37M 0.24M
Total cash from operating activities -2.90113M -2.03018M -0.68447M
Issuance of capital stock - 12.00M -
Depreciation - - -
Other cashflows from investing activities - - -
Dividends paid - - -
Change to inventory - - -
Change to account receivables - - -
Sale purchase of stock 0.00000M 12.00M 0.00000M
Other cashflows from financing activities 0.00000M -0.83379M -0.18152M
Change to netincome - - -
Capital expenditures 0.01M 0.00305M 0.34M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital 1.15M 0.56M -
Stock based compensation - - -
Other non cash items - - -
Free cash flow - -2.03322M -1.02470M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
COV
Cleo Diagnostics Ltd		 0.03 4.95% 0.53 - - 29.38 8.37
COH
Cochlear Ltd		 -2.015 1.10% 180.50 35.04 28.33 5.17 6.50 5.41 22.39
4DX
4DMEDICAL Ltd		 0.04 0.90% 4.47 - - 421.18 37.59 411.50 -7.2899
AVR
Anteris Technologies Global Corp		 0.28 3.26% 8.87 - - 495.24 162.25 283.45 -5.1986
PNV
Polynovo Ltd		 0.03 2.78% 0.93 92.50 30.40 4.58 7.52 4.45 89.43

Reports Covered

Stock Research & News

View All

Profile

Cleo Diagnostics Ltd, a biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property, testing the IP, and securing patents. Cleo Diagnostics Ltd was incorporated in 2021 and is based in Melbourne, Australia.

Cleo Diagnostics Ltd

480 Collins Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Dr. Richard Allman Ph.D. CEO & Exec. Director 1960
Dr. Andrew N. Stephens Chief Scientific Officer & Exec. Director NA
Prof. Thomas William Jobling Lead Medical Advisor & Independent Non-Exec. Director NA
Ms. Pauline M. Moffatt AAICD, B.Com., BCom, FGIA Company Sec. NA
Dr. Richard Allman Ph.D. CEO & Exec. Director 1960
Dr. Andrew N. Stephens Chief Scientific Officer & Exec. Director NA
Prof. Thomas William Jobling Lead Medical Advisor & Independent Non-Exec. Director NA
Ms. Pauline M. Moffatt AAICD, B.Com., BCom, FGIA Company Sec. NA
Dr. Richard Allman Ph.D. CEO & Exec. Director 1960
Dr. Andrew N. Stephens Chief Scientific Officer & Exec. Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.